- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05365503
Dissemination Strategies and Implementation Outcomes of Adolescent Character Strength Interventions.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a dissemination study whose objective is to explore the effectiveness, acceptability, and scalability of the Shamiri intervention when implemented in a large-scale naturalistic dissemination study in Kenyan secondary schools. Specifically, this study has two broad goals: 1) to test the effectiveness of Shamiri on mental health and psychosocial outcomes when delivered naturalistically on a large scale through either a centralized and de-centralized (train the trainers) administration, and 2) to examine and measure outcomes of these large-scale dissemination models.
For goal 1, participants will receive Shamiri directly through the Shamiri team or through an implementation partner. The investigators will measure mental health and psychosocial outcomes to determine if these outcomes compare to those reported in prior RCTs of Shamiri. The investigators hypothesize that participants receiving Shamiri will experience similar improvements in mental health and psychosocial outcomes as reported in previous RCTs. The investigators don't have a priori hypothesis on whether the mode through which the participants receive the intervention will affect intervention outcomes.
To achieve goal 2, investigators measure the following implementation related outcomes: intervention fidelity, cost, sustainment, acceptability, penetration, and cost-effectiveness. The investigators hypothesize that the Shamiri intervention will achieve high ratings in all intervention outcomes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nairobi, Kenya
- Shamiri Institute
-
-
Central Province
-
Kiambu, Central Province, Kenya
- Shamiri Institute
-
-
Eastern Province
-
Makueni, Eastern Province, Kenya
- Africa Mental Health Research and Training Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be high school students in one of the selected schools.
- Participants must be between the ages of 12 to 21.
Exclusion Criteria:
- There will be no other exclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Shamiri Intervention
The Shamiri intervention group will recieve a brief character strength intervention that will be delivered over the span of 4 weeks.
There will be four sessions each lasting one hour each.
|
The first two sessions focus on the concept of growth mindset, the third session focuses on gratitude, and the fourth and final session focuses on values.
In session one, participants are guided through a Growth mindset intervention designed to convey the idea that people and their situations can change for the better.
In session two, group leaders introduce a discussion and activities about effective strategies for growth.
Then, the group leaders introduce a framework for problem solving.
In session three, group leaders emphasize the importance of verbalizing and consciously thinking about Gratitude, as well as its benefits for well-being.
In the final session, participants are introduced to the concept of values.
Participants discuss stories of culturally pertinent role models, with an emphasis on the values these individuals display, and how their values guided their life decisions and led to success and happiness.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in anxiety symptoms from baseline to 1-month follow up
Time Frame: Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
Self-reported anxiety symptoms, measured by the Generalized Anxiety Disorder Screener
|
Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
|
Change in depression symptoms from baseline to 1-month follow up
Time Frame: Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
Self-reported depression symptoms as measured by the Patient Health Questionnaire - 8
|
Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
|
Change in perceived social support from baseline to 1-month follow up
Time Frame: Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
Self-reported sense of social support, measured by the Multidimensional Scale of Perceived Social Support, with a score range of 0-7, with higher scores indicating greater perception of social support
|
Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
|
Change in self-reported well-being from baseline to 1-month follow up
Time Frame: Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
Self-reported wellbeing, as measured by the Engagement, Perseverance, Optimism, Connectedness and Happiness Measure of Adolescent Well-Being, with a score range of 1-5, higher scores meaning better well-being
|
Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
|
Change in academic performance from baseline to 1-month follow up
Time Frame: Baseline (academic term pre-intervention) and up to 1-month post intervention
|
Academic performance, as measured by the average grade achieved from the school term before the intervention, the school term during which the intervention takes place, and the last term for which academic grades are available.
|
Baseline (academic term pre-intervention) and up to 1-month post intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in self-reported secondary control from baseline to 1-month follow up
Time Frame: Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
Self-reported participant sense of secondary control, or the ability to adjust oneself to hardships in such a way as to control their subjective emotional impact, measured by the 6-item short form of the Secondary Control Scale for Children (score range of 0-18, higher scores indicating greater perceived secondary control)
|
Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
|
Change in sense of meaning and purpose in life from baseline to 1-month follow up
Time Frame: Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
Self-reported sense of purpose and meaning in life, as measured by the Purpose in Life Scale-12, with a score range of 20-140, higher scores indicating greater perceived meaning in life
|
Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
|
Change in gratitude from baseline to 1-month follow up
Time Frame: Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
Self-reported gratitude, measured by a 6-item version of the Gratitude Questionnaire, with a score range of 6-48, with higher scores indicating higher gratitude
|
Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
|
Change in perceived control from baseline to 1-month follow up
Time Frame: Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
Self-reported sense of control over oneself and one's life, measured by the Perceived Control Scale for Children, with a score range of 0-24, with a higher score indicating higher perception of control over one's life
|
Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
|
Change in mental well-being from baseline to 1-month follow up
Time Frame: Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
Self-reported mental well-being of participants measured by the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS), with a score range of 7-35, higher scores indicating higher positive mental well-being
|
Baseline, 2-week mid-point, 4-week end-point, and 1-month follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tom L Osborn, Shamiri Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Templeton 2 Phase 2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Health Disorder
-
University Hospital, Strasbourg, FranceRecruitingMental Health DisorderFrance
-
Rutgers, The State University of New JerseyRecruiting
-
Virginia Commonwealth UniversityCompletedMental Health DisordersUnited States
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMental Health DisordersCongo
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedMental Health DisordersNorway
-
University of WarwickKing's College London; KU Leuven; University Hospital, Montpellier; Erasmus Medical... and other collaboratorsUnknownMental Health Disorder | Mental Health ImpairmentIreland, United Kingdom, Netherlands, Germany, Belgium, Croatia, France, Italy
-
York UniversityCanadian Institutes of Health Research (CIHR); North York General HospitalCompletedMental Health DisordersCanada
-
VA Boston Healthcare SystemUS Department of Veterans AffairsCompletedMental Health DisordersUnited States
-
Mindstate Design LabsCompleted
-
University of HaifaCompletedMental Health DisordersIsrael
Clinical Trials on Shamiri Intervention
-
Shamiri InstituteRecruiting
-
Biolux Research Holdings, Inc.TerminatedOrthodontic Tooth MovementCanada
-
Nottingham Trent UniversityUnknownOverweight and ObesityUnited Kingdom
-
University of Southern DenmarkTrygFonden, DenmarkUnknownObesity | Overweight | Metabolic Syndrome | ChildrenDenmark
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedColorectal Carcinoma | Healthy Subject | Health Status UnknownUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8United States
-
University of FloridaCompletedSensitivityUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnCancer Survivor | Peripheral Sensory Neuropathy
-
Vanderbilt UniversityCompletedMath Learning Disability | Reading Learning DisabilityUnited States